Chang Gung University

Chang Gung Memorial Hospital, Linkou

S&t Biomed Co., Ltd.

Kai-Ping Chang

Jau-Song Yu

Yu-Sun Chang

Chia-Hsun Hsieh

Chih-Ching Wu

Yi-Ting Chen

Chia-Yu Yang

Chun-Nan Ouyang

Chiao-Rou Liu

Wei-Fan Chiang

Lai-Chu See

Provided herein is a method for treating an oral cancer in a subject. According to embodiments of the present disclosure, the method comprises respectively obtaining a first and a second biological samples from a lesion site and a non-lesion site of the subject; respectively measuring the expression levels of CHEK1, PIK3CA, or PIK3CD in both biological samples by qRT-PCR thereby obtaining a first and a second expression level; determining the ratio of the first to the second expression level; and administering to the subject an effective amount of a checkpoint kinase 1 inhibitor when the ratio for CHEK1 is at least 1.7 or a phosphatidylinositol 3-kinase inhibitor when the ratio for PIK3CA is at least 2.4, or when the ratio for PIK3CD is at least 3.1.

Methods for treating oral cancers

Disclosed herein is a method of determining whether a subject has or is at risk of developing a cancer. The method comprises, obtaining a sample from the subject; determining the levels of at least two target polypeptides, which are selected from the group consisting of, ANXA2, HSPA5, KNG1 and MMP1; and assessing whether the subject has or is at risk of developing the cancer based on the levels of target polypeptides. The present method provides a potential means to diagnose and predict the occurrence of oral squamous cell carcinoma, and accordingly, the subject in need thereof could receive a suitable therapeutic regimen in time.

Method for cancer diagnosis and prognosis

A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3&#x3b1; expression level. Then, the MIP-3&#x3b1; expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3&#x3b1; expression level between the specimen and the control.

Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker

Growing community of inventors

Taipei, Taiwan

Kai-Ping Chang